ArticleF1000 medicine reports2012
Kinase inhibitors in the treatment of immune-mediated disease.
Article in F1000 medicine reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 57 citations in OpenAlex.
- Integrative in silico and in vivo Drosophila model studies reveal the anti-inflammatory, antioxidant, and anticancer properties of red radish microgreen extract.Scientific reports · 2025Article
- Acne exacerbation after tofacitinib treatment for alopecia areata.Dermatology reports · 2022Article
- The JAK2 inhibitor TG101209 exhibits anti-tumor and chemotherapeutic sensitizing effects on Burkitt lymphoma cells by inhibiting the JAK2/STAT3/c-MYB signaling axis.Cell death discovery · 2021Article
- Tackling Chronic Inflammation with Withanolide Phytochemicals-A Withaferin a Perspective.Antioxidants (Basel, Switzerland) · 2020Review
- Modulation of LPS-induced inflammatory cytokine production by a novel glycogen synthase kinase-3 inhibitor.European journal of pharmacology · 2020Article
- Review
- IL-23 signaling regulation of pro-inflammatory T-cell migration uncovered by phosphoproteomics.PLoS biology · 2020Article
- Essential Kinases and Transcriptional Regulators and Their Roles in Autoimmunity.Biomolecules · 2019Review
- Tuberculosis and impaired IL-23-dependent IFN-γ immunity in humans homozygous for a commonScience immunology · 2018Article
- Kinase inhibitors: the road ahead.Nature reviews. Drug discovery · 2018Review
- European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib.Therapeutics and clinical risk management · 2018Review
- The p38 MAPK Inhibitor SB203580 Abrogates Tumor Necrosis Factor-Induced Proliferative Expansion of Mouse CD4Frontiers in immunology · 2018Article
- Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Medicinal research reviews · 2018Review
- Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases.Journal of autoimmunity · 2017Review
- Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia.Scientific reports · 2017Article
- Conventional and novel stem cell based therapies for androgenic alopecia.Stem cells and cloning : advances and applications · 2017Review
- Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound-Kinase Activities: A Way toward Selective Promiscuity by Design?Journal of chemical information and modeling · 2016Article
- Therapeutic targets and emerging treatment options in gastrointestinal acute graft-versus-host disease.Expert opinion on orphan drugs · 2016Article
- Article
- Enhanced cardiovascular risk in rheumatoid arthritis: elucidation, assessment, and management.BioMed research international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Protein kinases are fundamental components of diverse signaling pathways, including immune cells. Their essential functions have made them effective therapeutic targets. Initially, the expectation was that a high degree of selectivity would be critical; however, with time, the use of "multikinase" inhibitors has expanded. Moreover, the spectrum of diseases in which kinase inhibitors are used has also expanded to include not only malignancies but also immune-mediated diseases. At present, thirteen kinase inhibitors have been approved in the United States, all for oncologic indications. However, there are a growing number of molecules, including several Janus kinase inhibitors, that are being tested in clinical trials for autoimmune diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel diseases. It appears likely that this new class of immunomodulatory drugs will have a major impact on the treatment of immune-mediated diseases in the near future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.